What Is Post-Cycle Therapy (PCT)? How It Works, When It Starts and What It Cannot Fix
What Is Post-Cycle Therapy (PCT)? How It Works, When It Starts and What It Cannot Fix
Post-cycle therapy (PCT) is the use of drugs after a steroid cycle ends to help restart natural testosterone production and support hormonal recovery after steroids, timed around how suppressed the HPG axis actually is rather than a fixed calendar day.
Post-Cycle Therapy: 3 Things the Evidence Shows
Post-cycle therapy is mostly discussed as folklore, but its two drug classes have real clinical data, and the recovery it is meant to accelerate has been measured in cohorts of cycle users.
A meta-analysis of 19 studies and 1,642 men found clomiphene raised total and free testosterone, LH, FSH, SHBG and estradiol significantly (Huijben 2022). In 400 men on long-term clomiphene, 88 percent reached normal testosterone and 8 percent reported side effects (Krzastek 2019).
In 49 men who had become azoospermic or severely oligospermic on testosterone or steroids, hCG-based combination therapy brought sperm back in 95.9 percent, after an average of 4.6 months (Wenker 2015).
Three months after stopping, 20.5 percent of 44 users still had low testosterone (Lykhonosov 2020); 11 percent of 100 cycle users were still below normal at the end of a one-year study (Smit 2021). Recovery tracked duration of use, dose and compound.
What PCT is for: shortening the gap between the last dose clearing and the axis running on its own. What it is not: a guarantee. A SERM can only amplify a signal the pituitary is capable of sending, and the testes still have to answer. The bloodwork that tells those two apart is the most important part of this guide.
The axis: hypothalamus, pituitary, testes, and the feedback loop steroids override.
What each PCT drug does: SERMs at the top of the axis, hCG at the bottom, and why aromatase inhibitors are usually the wrong tool.
When PCT starts, by ester, and the bloodwork before and after it.
What PCT cannot fix: primary testicular failure after long or repeated use, and the five mistakes that turn a recovery into a relapse.
How the Hypothalamic-Pituitary-Testicular Axis Works, and How Steroids Shut It Down
Post-cycle therapy only makes sense against the chain it is trying to restart. Testosterone is produced by a three-level chain. The hypothalamus releases GnRH in pulses; the pituitary answers each pulse with LH and FSH; LH drives the Leydig cells to make testosterone and FSH drives the Sertoli cells to support sperm production. The chain regulates itself by negative feedback: when testosterone and the estradiol made from it are high, the hypothalamus slows its pulses and the pituitary releases less LH, and when they are low the reverse happens. The set point keeps a healthy man in the normal range without any conscious input.
Exogenous androgens hijack the feedback. The hypothalamus and pituitary read a high androgen and estrogen signal and behave as if the testes were over-producing: GnRH pulses stop, LH and FSH fall to near zero, and the Leydig cells, with no LH, stop making testosterone and shrink. Every anabolic steroid does this, oral or injectable, mild or strong, because the mechanism is receptor binding at the top of the axis, not a property of one molecule. What varies is depth and duration. The full mechanism is in why steroids cause testosterone suppression.
The diagram is the whole logic of post-cycle therapy. Steroids press on the top of the chain. SERMs release one of the two brakes at the top, the estrogen brake, which is why they cannot work while the androgen brake is still being pressed by an ester that has not cleared. hCG bypasses the top entirely and acts on the testes as a stand-in for LH, which is why it can keep the Leydig cells responsive but cannot teach the pituitary to signal again. Recovery is complete only when the top of the chain sends its own LH and the bottom answers with its own testosterone, with no drug in the picture.
What Post-Cycle Therapy Drugs Actually Do
Three drug classes appear in post-cycle therapy. Two of them have a mechanism that matches the problem; the third is usually misapplied. Doses and schedules are not given here; the point is what each does and does not do.
| Drug class | Where it acts | What it does | What it cannot do | Status |
|---|---|---|---|---|
| SERMs clomiphene, tamoxifen, enclomiphene | Estrogen receptors in the hypothalamus and pituitary | Block estrogen's negative feedback, so GnRH, LH and FSH rise and the testes are stimulated. Meta-analysis of 1,642 men: total and free testosterone, LH and FSH all increase (Huijben 2022). Long-term data: 88 percent eugonadal, 8 percent side effects (Krzastek 2019). | Work only once the androgen brake is off (ester cleared), and only if the testes can respond. Raise estradiol as well as testosterone. Symptom relief on the drug is not proof the axis works without it. | ● Core PCT |
| hCG human chorionic gonadotropin | LH receptors on the Leydig cells | Mimics LH, driving testosterone and intratesticular testosterone directly; used late in a cycle or before SERMs to keep the testes responsive, and with SERMs to restore sperm. 95.9 percent of azoospermic men on hCG-based therapy recovered sperm, average 4.6 months (Wenker 2015). | Does nothing for the pituitary; it is itself suppressive at the top of the axis while used, so it is a bridge, not a recovery. Sustained use without a SERM keeps the axis off. | ● Bridge and fertility |
| Aromatase inhibitors anastrozole, letrozole | Aromatase enzyme, body-wide | Lower estradiol. Sometimes used for gynecomastia symptoms during a cycle. | Estradiol is part of the signal the recovering axis needs; crushing it during PCT produces joint pain, low libido, mood collapse and can blunt the LH response the SERM is trying to produce. Rarely justified in PCT. | ● Usually wrong tool |
A different view: what the clinical series measured. Outcomes of SERM and hCG treatment in men with low testosterone or suppressed sperm production.
Two caveats belong next to those numbers. The clomiphene series are men treated for hypogonadism under a clinician, on the drug continuously, not men running a self-designed four-week course after a cycle; the outcome they show is that SERMs move the axis, not that any given PCT works. And Grant's 2023 survey of endocrinologists found wide variation in how anabolic steroid-induced hypogonadism is managed: SERMs, hCG and, when the testes have failed, replacement therapy, chosen by the bloodwork pattern rather than by a fixed protocol. The 2022 evidence review in family practice (Are SERMs safe and effective?) reaches the same conclusion for hypogonadal men generally: effective, reasonably safe, and a prescribing decision.
When Post-Cycle Therapy Starts: The Ester Decides
Post-cycle therapy starts when the ester has cleared, because a SERM releases the estrogen brake and does nothing about the androgen brake. While a long ester is still releasing testosterone at a suppressive level, LH stays down whatever is taken, and the planned PCT is spent on days when it cannot work. The start date is therefore set by the slowest ester in the cycle. The measured cypionate curve is the reference: after a 200 mg injection, testosterone is back at the untreated baseline by day 13 to 14 (Nankin 1987), which is where the two-week convention for enanthate and cypionate comes from.
Orals and short esters: days
Oral 17-alpha-alkylated steroids clear in one to three days; trenbolone acetate and testosterone propionate in two to four. Clearance is fast, but the suppression built over a long oral cycle is not, so the same bloodwork applies.
Enanthate and cypionate: about two weeks
Half-lives of 4 to 6 days; about 14 days after the last injection, 14 to 18 for cypionate and trenbolone enanthate. High doses and large volumes extend the tail; a blood test at day 14 confirms it.
Nandrolone decanoate and blends: three weeks or more
Decanoate has a half-life of about 15 days, so three to four weeks minimum, or stop the nandrolone four to six weeks before the testosterone and time from the testosterone. Mixed-ester blends are timed to their decanoate fraction, 18 to 21 days.
Injectable undecanoate: months, bloodwork-timed
Half-life about 34 days; five half-lives is five months. No rule of thumb applies. Anyone coming off undecanoate who wants the axis back is in a clinician's territory.
The full compound-by-compound table, with the half-life data behind each window, is in when to start PCT.
The Bloodwork That Proves Post-Cycle Therapy Worked
Post-cycle therapy is judged by two panels, and the timing of the second is the part most often got wrong. A panel drawn while clomiphene or tamoxifen is still on board measures the drug: LH and FSH are high because the SERM is holding the estrogen brake off. The question PCT is meant to answer is what the axis sustains on its own, and that is visible only 4 to 6 weeks after the last dose.
| Draw | Markers | What it answers | Status |
|---|---|---|---|
| Pre-cycle baseline | Total testosterone (two morning draws), LH, FSH, SHBG, estradiol by LC-MS/MS, CBC, lipids, liver enzymes; semen analysis if fertility matters | The only reference point that means anything later. 410 ng/dL is a full recovery for a man whose baseline was 400 and half a recovery for one whose baseline was 700. | ● Decisive |
| Panel one: before the first PCT dose | Total testosterone, LH, FSH, estradiol, CBC, lipids, liver enzymes | Confirms the ester has cleared (testosterone low) and records the depth of suppression (LH, FSH near zero). Testosterone still high means wait. | ● Decisive |
| Panel two: 4 to 6 weeks after the last PCT dose | Total testosterone, LH, FSH; estradiol, SHBG and free testosterone if symptoms do not match the total | The verdict. LH 3 to 8 IU/L with testosterone trending to baseline is recovery; LH near zero with low testosterone is a stalled signal; LH above range with low testosterone is testes that are not answering. | ● Decisive |
| Confirmation: about 3 months post-cycle | Hormones again; CBC, HDL, liver enzymes; semen analysis if fertility matters | Sustained recovery; hematocrit and HDL back toward baseline; sperm, which lags testosterone by months. | ● Health and fertility |
Free testosterone and SHBG deserve a note. SHBG often rises during recovery, and a SERM raises it further, so total testosterone can look normal while the free fraction is still low and the man still feels hypogonadal; total vs free testosterone and SHBG explained cover the reading. The full panel with the numbers that mean recovery, repeat or referral is in PCT bloodwork; the pre-cycle baseline in blood tests before steroids.
What Post-Cycle Therapy Cannot Fix
Post-cycle therapy works on the top of the axis. It has no effect on Leydig cells that have lost the capacity to respond, and after long or repeated use that is exactly where the problem often sits. The former users in Kanayama's series averaged 131 ng/dL less testosterone than non-using weightlifters, had smaller testes, and five of nineteen were below 200 ng/dL after 3 to 26 months off. The bloodwork signature of that state is high LH and FSH with low testosterone: the pituitary is already shouting and more SERM cannot make it shout louder. Rahnema's review calls this anabolic steroid-induced hypogonadism and lists the clinical options as hCG, SERMs under supervision, or replacement.
The other thing post-cycle therapy cannot do is hurry sperm. Spermatogenesis takes about 74 days per cycle and restarts only once FSH and intratesticular testosterone are back; the HAARLEM cohort had normal testosterone three months after the cycle and a sperm count still 61.7 million below baseline. Desai's 2022 review sets out how clinicians manage that with hCG and FSH when it does not resolve. Sperm is a separate clock, and it is covered in fertility and suppression on steroids, with the full timeline of all three stages in the PCT recovery timeline and the mechanism of restart in hormonal recovery after steroids.
Testosterone still low with LH and FSH either near zero or above range at 3 to 4 months post-cycle, confirmed on a repeat draw, is an endocrinology appointment with every panel in hand. Another round of PCT is the wrong answer to both patterns, and the tail is not small: 20 percent still low at three months in one cohort, 27 percent below the reference limit years later in another.
5 Post-Cycle Therapy Mistakes That Turn Recovery Into Relapse
1. Starting before the ester has cleared. The SERM is spent fighting the depot. Time from the slowest compound and confirm with a pre-PCT panel.
2. Judging recovery by testosterone alone. Without LH and FSH there is no way to tell a recovering axis from a drug-supported one or a stalled one at the same testosterone value.
3. Crushing estradiol with an aromatase inhibitor. The recovering axis needs its estrogen signal; a SERM already handles the feedback side. Low estradiol during PCT means joint pain, flat mood and a blunted LH response.
4. Stopping when symptoms improve. The lift in the first weeks is the drug. Stopping before the axis sustains itself drops the hormones again and resets the clock. Duration is decided by bloodwork drawn after the drug has cleared.
5. Running PCT with no bloodwork at all. No baseline, no pre-PCT panel, no post-PCT panel means no way to distinguish recovery from assumption, and no way to catch the one man in five who needs a doctor rather than another course.
Post-Cycle Therapy: Common Questions
What is post-cycle therapy (PCT)?
Post-cycle therapy is the use of drugs, mainly the SERMs clomiphene and tamoxifen and sometimes hCG, to restart the body's own testosterone production after a steroid cycle has suppressed it. SERMs block estrogen feedback at the hypothalamus and pituitary so LH and FSH rise; hCG stimulates the testes directly. PCT accelerates a recovery the axis has to complete itself.
Is PCT necessary after every steroid cycle?
Post-cycle therapy is not automatic. Every anabolic steroid suppresses the axis, so every cycle is followed by a recovery period. Whether drugs shorten it usefully depends on the depth of suppression; the cohorts show most men recover testosterone within months, and about one in five has not by three months. What is always necessary is bloodwork before and after, whichever route is taken.
How does PCT work?
Post-cycle therapy works at both ends of the axis. SERMs occupy estrogen receptors in the hypothalamus and pituitary, removing estrogen's negative feedback; GnRH pulses resume, LH and FSH rise, and the testes are stimulated to make testosterone and sperm. hCG works at the other end by mimicking LH at the testes. Neither repairs the axis; they stimulate it while it re-establishes its own control.
When should PCT start after a cycle?
When the slowest ester in the cycle has cleared: one to three days after orals, two to four after propionate or trenbolone acetate, about two weeks after enanthate or cypionate, three to four weeks after nandrolone decanoate, and six weeks or more after injectable undecanoate, confirmed by bloodwork.
Do I need hCG for PCT?
Not always. hCG is used as a bridge at the end of long cycles to keep the testes responsive, and with SERMs when sperm production needs to be restored; in one series 95.9 percent of azoospermic men recovered sperm on hCG-based therapy. It is suppressive at the pituitary while used, so it is not a recovery on its own.
Should I take an aromatase inhibitor during PCT?
Usually not. The recovering axis uses estradiol as part of its signalling, and SERMs already block the estrogen feedback that matters. Aggressively lowering estradiol during PCT causes joint pain, low libido and flat mood and can blunt the LH response. Estradiol is monitored, not automatically suppressed.
How do I know PCT has worked?
Post-cycle therapy is judged by a panel drawn 4 to 6 weeks after the last PCT dose: LH and FSH present, roughly 3 to 8 IU/L for LH, and total testosterone trending toward the pre-cycle baseline. Testosterone in range while on the drug proves nothing; values that hold after the drug has cleared do.
What if PCT does not work?
Repeat the panel under proper conditions. If testosterone is still low with LH and FSH near zero, the signal has not restarted; if LH and FSH are above range with low testosterone, the testes are not responding. Both are reasons to see an endocrinologist at 3 to 4 months post-cycle, not to run another course.
References
All citations are peer-reviewed studies verified via PubMed. Reference links are dofollow to support open science. The PCT protocols and recovery timelines cited in this article are sourced directly from the primary publications below.
Related PCT Guides
All guides are evidence-based, PMID-verified, and written for people navigating post-cycle therapy and hormonal recovery.
Final Educational Note
This post-cycle therapy guide explains what the therapy is and how its drugs act, for educational and harm-reduction purposes. Clomiphene, tamoxifen and hCG are prescription medicines; nothing here is a dose, a protocol, or medical advice, and none of it replaces an endocrinologist reading your own bloodwork.
MuscleScience does not sell or supply any compound. For the wider series, start at the PCT hub and the steroids hub. Author names are pseudonyms; see the About page and Disclaimer.
